nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

08.02.2018 | Original Article

Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis

verfasst von: Tao Jiang, Meng Qiao, Chao Zhao, Xuefei Li, Guanghui Gao, Chunxia Su, Shengxiang Ren, Caicun Zhou

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

To investigate the association between pretreatment blood neutrophil-to-lymphocyte ratio (NLR) and clinical outcomes for advanced-stage cancer patients treated with immunotherapy.

Methods

We conducted a comprehensive literature search to assess the relationship between pretreatment blood NLR and overall survival (OS) or progression-free survival (PFS) in advanced-stage cancer patients treated with immunotherapy. Published data including hazard ratios (HRs) and related 95% confidence interval (CI) were extracted. Pooled estimates of treatment outcomes were calculated using RevMan 5.3.5.

Results

Twenty-seven studies with 4647 patients were included in the current study. The pooled results suggested that high pretreatment blood NLR was correlated with significant shorter OS (HR = 1.98, 95% CI 1.66–2.36, P < 0.001) and PFS (HR = 1.78, 95% CI 1.48–2.15, P < 0.001). Subgroup analysis stratified by study targets revealed that anti-VEGF/VEGFR therapy (HR = 2.04, 95% CI 1.61–2.60, P < 0.001) and immune checkpoints blockade (HR = 2.16, 95% CI 1.86–2.51, P < 0.001) were significantly associated with inferior OS while other targets (HR = 1.63, 95% CI 0.89–2.99, P = 0.120) were not associated with OS. There was no correlation between distinct NLR cutoff values and OS (\({r^{{\text{Pearson}}}}\) = 0.218, P = 0.329) or PFS benefit (\({r^{{\text{Pearson}}}}\) = − 0.386, P = 0.140). Of note, HRs of PFS showed significant correlation with HRs of OS (\({r^{{\text{Pearson}}}}\) = 0.656, P = 0.015).

Conclusion

Elevated pretreatment blood NLR was a promising prognostic and predictive biomarker for advanced-stage cancer patients treated with immunotherapy.

Nur mit Berechtigung zugänglich

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. https://doi.org/10.3322/caac.21262 CrossRefPubMed

Jiang T, Zhou C (2015) The past, present and future of immunotherapy against tumor. Transl Lung Cancer Res 4(3):253–264. https://doi.org/10.3978/j.issn.2218-6751.2015.01.06 PubMedPubMedCentral

Farkona S, Diamandis EP, Blasutig IM (2016) Cancer immunotherapy: the beginning of the end of cancer? BMC Med 14:73. https://doi.org/10.1186/s12916-016-0623-5 CrossRefPubMedPubMedCentral

Nishino M, Ramaiya NH, Hatabu H, Hodi FS (2017) Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol 14(11):655–668. https://doi.org/10.1038/nrclinonc.2017.88 CrossRefPubMed

Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1):1–10. https://doi.org/10.1016/j.immuni.2013.07.012 CrossRefPubMed

Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer-immune set point. Nature 541(7637):321–330. https://doi.org/10.1038/nature21349 CrossRefPubMed

Palucka AK, Coussens LM (2016) The Basis of Oncoimmunology. Cell 164(6):1233–1247. https://doi.org/10.1016/j.cell.2016.01.049 CrossRefPubMedPubMedCentral

Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264. https://doi.org/10.1038/nrc3239 CrossRefPubMedPubMedCentral

Hoos A (2016) Development of immuno-oncology drugs—from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov 15(4):235–247. https://doi.org/10.1038/nrd.2015.35 CrossRefPubMed

10.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013 CrossRefPubMed

11.

Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C, Zhang H, Cheng G, Song X, Lu Y, Pan H, Zheng W, Yin AY (2015) BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol 33(19):2197–2204. https://doi.org/10.1200/JCO.2014.59.4424 CrossRefPubMed

12.

Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Perol M (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384(9944):665–673. https://doi.org/10.1016/S0140-6736(14)60845-X CrossRefPubMed

13.

Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J, Investigators RT (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383(9911):31–39. https://doi.org/10.1016/S0140-6736(13)61719-5 CrossRefPubMed

14.

Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M, Investigators RT (2015) Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 16(7):859–870. https://doi.org/10.1016/S1470-2045(15)00050-9 CrossRefPubMed

15.

Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausova J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F, Investigators RS (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16(5):499–508. https://doi.org/10.1016/S1470-2045(15)70127-0 CrossRefPubMed

16.

Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17(12):e542–e551. https://doi.org/10.1016/S1470-2045(16)30406-5 CrossRefPubMedPubMedCentral

17.

Sacher AG, Gandhi L (2016) Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer: a review. JAMA Oncol 2(9):1217–1222. https://doi.org/10.1001/jamaoncol.2016.0639 CrossRefPubMed

18.

Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16(5):275–287. https://doi.org/10.1038/nrc.2016.36 CrossRefPubMedPubMedCentral

19.

Lesterhuis WJ, Bosco A, Millward MJ, Small M, Nowak AK, Lake RA (2017) Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. Nat Rev Drug Discov 16(4):264–272. https://doi.org/10.1038/nrd.2016.233 CrossRefPubMed

20.

Chae YK, Pan A, Davis AA, Raparia K, Mohindra NA, Matsangou M, Giles FJ (2016) Biomarkers for PD-1/PD-L1 Blockade therapy in non-small-cell lung cancer: Is PD-L1 expression a good marker for patient selection? Clin Lung Cancer 17(5):350–361. https://doi.org/10.1016/j.cllc.2016.03.011 CrossRefPubMed

21.

Funakoshi T, Lee CH, Hsieh JJ (2014) A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma. Cancer Treat Rev 40(4):533–547. https://doi.org/10.1016/j.ctrv.2013.11.008 CrossRefPubMed

22.

O’Connor JP, Jayson GC (2012) Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors? Clin Cancer Res 18(24):6588–6598. https://doi.org/10.1158/1078-0432.CCR-12-1501 CrossRefPubMed

23.

Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899. https://doi.org/10.1016/j.cell.2010.01.025 CrossRefPubMedPubMedCentral

24.

Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA (2013) Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 13(11):759–771. https://doi.org/10.1038/nrc3611 CrossRefPubMed

25.

Crusz SM, Balkwill FR (2015) Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol 12(10):584–596. https://doi.org/10.1038/nrclinonc.2015.105 CrossRefPubMed

26.

Dougan M, Dranoff G (2009) Immune therapy for cancer. Annu Rev Immunol 27:83–117. https://doi.org/10.1146/annurev.immunol.021908.132544 CrossRefPubMed

27.

McMillan DC (2013) The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 39(5):534–540. https://doi.org/10.1016/j.ctrv.2012.08.003 CrossRefPubMed

28.

Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Di Giacomo AM, Giannarelli D, Cappellini GC, De Galitiis F, Marchetti P, Amato G, Lazzeri A, Pala L, Cocorocchio E, Martinoli C (2015) Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer 112(12):1904–1910. https://doi.org/10.1038/bjc.2015.180 CrossRefPubMedPubMedCentral

29.

Ferrucci PF, Ascierto PA, Pigozzo J, Del Vecchio M, Maio M, Antonini Cappellini GC, Guidoboni M, Queirolo P, Savoia P, Mandala M, Simeone E, Valpione S, Altomonte M, Spagnolo F, Cocorocchio E, Gandini S, Giannarelli D, Martinoli C (2016) Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol 27(4):732–738. https://doi.org/10.1093/annonc/mdw016 CrossRefPubMed

30.

Kuzman JA, Stenehjem DD, Merriman J, Agarwal AM, Patel SB, Hahn AW, Alex A, Albertson D, Gill DM, Agarwal N (2017) Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma. BMC Urol 17(1):1. https://doi.org/10.1186/s12894-016-0192-0 CrossRefPubMedPubMedCentral

31.

Park YH, Ku JH, Kwak C, Kim HH (2014) Post-treatment neutrophil-to-lymphocyte ratio in predicting prognosis in patients with metastatic clear cell renal cell carcinoma receiving sunitinib as first line therapy. Springerplus 3:243. https://doi.org/10.1186/2193-1801-3-243 CrossRefPubMedPubMedCentral

32.

Mei Z, Shi L, Wang B, Yang J, Xiao Z, Du P, Wang Q, Yang W (2017) Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: a systematic review and meta-analysis of 66 cohort studies. Cancer Treat Rev 58:1–13. https://doi.org/10.1016/j.ctrv.2017.05.005 CrossRefPubMed

33.

Hayden JA, Cote P, Bombardier C (2006) Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 144(6):427–437CrossRefPubMed

34.

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16. https://doi.org/10.1186/1745-6215-8-16 CrossRefPubMedPubMedCentral

35.

Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, Carducci MA (2012) The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer 48(2):202–208. https://doi.org/10.1016/j.ejca.2011.09.001 CrossRefPubMed

36.

Botta C, Barbieri V, Ciliberto D, Rossi A, Rocco D, Addeo R, Staropoli N, Pastina P, Marvaso G, Martellucci I, Guglielmo A, Pirtoli L, Sperlongano P, Gridelli C, Caraglia M, Tassone P, Tagliaferri P, Correale P (2013) Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther 14(6):469–475. https://doi.org/10.4161/cbt.24425 CrossRefPubMedPubMedCentral

37.

Cetin B, Berk V, Kaplan MA, Afsar B, Tufan G, Ozkan M, Isikdogan A, Benekli M, Coskun U, Buyukberber S (2013) Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma? Clin Genitourin Cancer 11(2):141–148. https://doi.org/10.1016/j.clgc.2012.09.001 CrossRefPubMed

38.

Dirican A, Kucukzeybek Y, Erten C, Somali I, Demir L, Can A, Payzin KB, Bayoglu IV, Akyol M, Yildiz Y, Koeseoglu M, Alacacioglu A, Tarhan MO (2013) Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. Asian Pac J Cancer Prev 14(3):2101–2105CrossRefPubMed

39.

Kobayashi M, Kubo T, Komatsu K, Fujisaki A, Terauchi F, Natsui S, Nukui A, Kurokawa S, Morita T (2013) Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy. Med Oncol 30(2):556. https://doi.org/10.1007/s12032-013-0556-1 CrossRefPubMed

40.

Zheng YB, Zhao W, Liu B, Lu LG, He X, Huang JW, Li Y, Hu BS (2013) The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev 14(9):5527–5531CrossRefPubMed

41.

da Fonseca LG, Barroso-Sousa R, Bento Ada S, Blanco BP, Valente GL, Pfiffer TE, Hoff PM, Sabbaga J (2014) Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Med Oncol 31(11):264. https://doi.org/10.1007/s12032-014-0264-5 CrossRefPubMed

42.

Gunduz S, Mutlu H, Uysal M, Coskun HS, Bozcuk H (2014) Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors. Asian Pac J Cancer Prev 15(8):3801–3804CrossRefPubMed

43.

Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Hammers H, Eisenberger MA, Sinibaldi V, Pili R, Hayat H, Kovel S, Sella A, Boursi B, Weitzen R, Mermershtain W, Rouvinov K, Berger R, Carducci MA (2014) Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib. Oncologist 19(1):51–60. https://doi.org/10.1634/theoncologist.2012-0335 CrossRefPubMed

44.

Livne-Segev D, Gottfried M, Maimon N, Peer A, Neumann A, Hayat H, Kovel S, Sella A, Mermershtain W, Rouvinov K, Boursi B, Weitzen R, Berger R, Keizman D (2014) Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors. Isr Med Assoc J 16(6):347–351PubMed

45.

Wang HK, Zhang HL, Zhu Y, Yao XD, Zhang SL, Dai B, Shen YJ, Zhu YP, Shi GH, Qin XJ, Ma CG, Lin GW, Xiao WJ, Ye DW (2014) A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma. Future Oncol 10(12):1941–1951. https://doi.org/10.2217/fon.14.131 CrossRefPubMed

46.

Namikawa T, Fukudome I, Ogawa M, Munekage E, Munekage M, Shiga M, Maeda H, Kitagawa H, Kobayashi M, Hanazaki K (2015) Clinical efficacy of protein-bound polysaccharide K in patients with gastric cancer undergoing chemotherapy with an oral fluoropyrimidine (S-1). Eur J Surg Oncol 41(6):795–800. https://doi.org/10.1016/j.ejso.2015.02.012 CrossRefPubMed

47.

Santoni M, Buti S, Conti A, Porta C, Procopio G, Sternberg CN, Bracarda S, Basso U, De Giorgi U, Rizzo M, Derosa L, Ortega C, Massari F, Milella M, Bersanelli M, Cerbone L, Muzzonigro G, Burattini L, Montironi R, Santini D, Cascinu S (2015) Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Target Oncol 10(4):517–522. https://doi.org/10.1007/s11523-014-0356-3 CrossRefPubMed

48.

Casadei Gardini A, Scarpi E, Faloppi L, Scartozzi M, Silvestris N, Santini D, de Stefano G, Marisi G, Negri FV, Foschi FG, Valgiusti M, Ercolani G, Frassineti GL (2016) Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. Oncotarget 7(41):67142–67149. https://doi.org/10.18632/oncotarget.11565 PubMed

49.

Chrom P, Stec R, Semeniuk-Wojtas A, Bodnar L, Spencer NJ, Szczylik C (2016) Fuhrman grade and neutrophil-to-lymphocyte ratio influence on survival in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. Clin Genitourin Cancer 14(5):457–464. https://doi.org/10.1016/j.clgc.2016.02.005 CrossRefPubMed

50.

Keizman D, Sarid D, Lee JL, Sella A, Gottfried M, Hammers H, Eisenberger MA, Carducci MA, Sinibaldi V, Neiman V, Rosenbaum E, Peer A, Neumann A, Mermershtain W, Rouvinov K, Berger R, Yildiz I (2016) Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib. Oncologist 21(10):1212–1217. https://doi.org/10.1634/theoncologist.2015-0428 CrossRefPubMedPubMedCentral

51.

Passardi A, Scarpi E, Cavanna L, Dall’Agata M, Tassinari D, Leo S, Bernardini I, Gelsomino F, Tamberi S, Brandes AA, Tenti E, Vespignani R, Frassineti GL, Amadori D, De Giorgi U (2016) Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Oncotarget 7(22):33210–33219. https://doi.org/10.18632/oncotarget.8901 CrossRefPubMedPubMedCentral

52.

Taipale K, Liikanen I, Koski A, Heiskanen R, Kanerva A, Hemminki O, Oksanen M, Gronberg-Vaha-Koskela S, Hemminki K, Joensuu T, Hemminki A (2016) Predictive and prognostic clinical variables in cancer patients treated with adenoviral oncolytic immunotherapy. Mol Ther 24(7):1323–1332. https://doi.org/10.1038/mt.2016.67 CrossRefPubMedPubMedCentral

53.

Zhang GM, Zhu Y, Gu WJ, Zhang HL, Shi GH, Ye DW (2016) Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy. Int J Clin Oncol 21(2):373–378. https://doi.org/10.1007/s10147-015-0894-4 CrossRefPubMed

54.

Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson JC, Stonehouse-Lee S, Sherry VE, Gilbert E, Eaby-Sandy B, Mutale F, DiLullo G, Cohen RB, Vachani A, Langer CJ (2017) Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer 106:1–7. https://doi.org/10.1016/j.lungcan.2017.01.013 CrossRefPubMed

55.

Cassidy MR, Wolchok RE, Zheng J, Panageas KS, Wolchok JD, Coit D, Postow MA, Ariyan C (2017) Neutrophil to lymphocyte ratio is associated with outcome during ipilimumab treatment. EBioMedicine 18:56–61. https://doi.org/10.1016/j.ebiom.2017.03.029 CrossRefPubMedPubMedCentral

56.

Jung M, Lee J, Kim TM, Lee DH, Kang JH, Oh SY, Lee SJ, Shin SJ (2017) Ipilimumab real-world efficacy and safety in korean melanoma patients from the korean named-patient program cohort. Cancer Res Treat 49(1):44–53. https://doi.org/10.4143/crt.2016.024 CrossRefPubMed

57.

Tanaka N, Mizuno R, Yasumizu Y, Ito K, Shirotake S, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Oya M (2017) Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: a proposal of the modified-IMDC risk model. Urol Oncol 35(2):39.e19–39.e28. https://doi.org/10.1016/j.urolonc.2016.10.001 CrossRef

58.

Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106(6):dju124. https://doi.org/10.1093/jnci/dju124 CrossRefPubMed

59.

Kraus S, Arber N (2009) Inflammation and colorectal cancer. Curr Opin Pharmacol 9(4):405–10. https://doi.org/10.1016/j.coph.2009.06.006 CrossRefPubMed

60.

Okazaki IM, Kotani A, Honjo T (2007) Role of AID in tumorigenesis. Adv Immunol 94:245–73. https://doi.org/10.1016/S0065-2776(06)94008-5 CrossRefPubMed

61.

Oguma K, Oshima H, Aoki M, Uchio R, Naka K, Nakamura S, Hirao A, Saya H, Taketo MM, Oshima M (2008) Activated macrophages promote Wnt signalling through tumour necrosis factor-alpha in gastric tumour cells. EMBO J 27(12):1671–1681. https://doi.org/10.1038/emboj.2008.105 CrossRefPubMedPubMedCentral

62.

Hussain SP, Harris CC (2007) Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 121(11):2373–2380. https://doi.org/10.1002/ijc.23173 CrossRefPubMed

63.

Treffers LW, Hiemstra IH, Kuijpers TW, van den Berg TK, Matlung HL (2016) Neutrophils in cancer. Immunol Rev 273(1):312–28. https://doi.org/10.1111/imr.12444 CrossRefPubMed

64.

Kargl J, Busch SE, Yang GH, Kim KH, Hanke ML, Metz HE, Hubbard JJ, Lee SM, Madtes DK, McIntosh MW, Houghton AM (2017) Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat Commun 8:14381. https://doi.org/10.1038/ncomms14381 CrossRefPubMedPubMedCentral

65.

Souto JC, Vila L, Bru A (2011) Polymorphonuclear neutrophils and cancer: intense and sustained neutrophilia as a treatment against solid tumors. Med Res Rev 31(3):311–63. https://doi.org/10.1002/med.20185 CrossRefPubMed

66.

Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW (2011) The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 105(1):93–103. https://doi.org/10.1038/bjc.2011.189 CrossRefPubMedPubMedCentral

67.

Chen F, Zhuang X, Lin L, Yu P, Wang Y, Shi Y, Hu G, Sun Y (2015) New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med 13:45. https://doi.org/10.1186/s12916-015-0278-7 CrossRefPubMedPubMedCentral

Titel: Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis
verfasst von: Tao Jiang
Meng Qiao
Chao Zhao
Xuefei Li
Guanghui Gao
Chunxia Su
Shengxiang Ren
Caicun Zhou
Publikationsdatum: 08.02.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 5/2018
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-018-2126-z

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2018

TriCurin, a synergistic formulation of curcumin, resveratrol, and epicatechin gallate, repolarizes tumor-associated macrophages and triggers an immune response to cause suppression of HPV+ tumors

Identification of tumor-reactive B cells and systemic IgG in breast cancer based on clonal frequency in the sentinel lymph node

Cancer immunotherapy in patients with brain metastases

Impaired lymphocyte function in patients with hepatic malignancies after selective internal radiotherapy

Early detection of hepatocellular carcinoma using autoantibody profiles from a panel of tumor-associated antigens

The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models

Neu im Fachgebiet Onkologie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Update Onkologie